心房颤动和心力衰竭是两种常见的心血管疾病,两者具有很多相同的危险因素,常合并存在并相互促进,且房颤合并心衰时较任一疾病预后更差。本文旨在总结近年来沙库巴曲缬沙坦在治疗房颤合并心衰方面的研究进展,探讨沙库巴曲缬沙坦能否成为...心房颤动和心力衰竭是两种常见的心血管疾病,两者具有很多相同的危险因素,常合并存在并相互促进,且房颤合并心衰时较任一疾病预后更差。本文旨在总结近年来沙库巴曲缬沙坦在治疗房颤合并心衰方面的研究进展,探讨沙库巴曲缬沙坦能否成为治疗房颤合并心衰的一线用药。Atrial fibrillation and heart failure are two common cardiovascular diseases. They have many of the same risk factors, often coexist and promote each other, and the prognosis of atrial fibrillation combined with heart failure is worse than either disease. This article aims to summarize the research progress of sacubitril/valsartan in the treatment of atrial fibrillation complicated with heart failure in recent years, and to explore whether sacubitril/valsartan can be the first-line drug for the treatment of atrial fibrillation complicated with heart failure.展开更多
南京电子器件研究所基于芯片微凸点制备工艺和倒装互连工艺,进行了GaAs,GaN等晶圆级异构集成3D芯片互连工艺的研究,实现了芯片与芯片堆叠(Die to die,D2D)到芯片与圆片堆叠(Die to wafer,D2W)的技术性突破。芯粒间采用耐腐蚀、抗氧化、...南京电子器件研究所基于芯片微凸点制备工艺和倒装互连工艺,进行了GaAs,GaN等晶圆级异构集成3D芯片互连工艺的研究,实现了芯片与芯片堆叠(Die to die,D2D)到芯片与圆片堆叠(Die to wafer,D2W)的技术性突破。芯粒间采用耐腐蚀、抗氧化、有良好塑性变形的金凸点作为互连材料。展开更多
文摘心房颤动和心力衰竭是两种常见的心血管疾病,两者具有很多相同的危险因素,常合并存在并相互促进,且房颤合并心衰时较任一疾病预后更差。本文旨在总结近年来沙库巴曲缬沙坦在治疗房颤合并心衰方面的研究进展,探讨沙库巴曲缬沙坦能否成为治疗房颤合并心衰的一线用药。Atrial fibrillation and heart failure are two common cardiovascular diseases. They have many of the same risk factors, often coexist and promote each other, and the prognosis of atrial fibrillation combined with heart failure is worse than either disease. This article aims to summarize the research progress of sacubitril/valsartan in the treatment of atrial fibrillation complicated with heart failure in recent years, and to explore whether sacubitril/valsartan can be the first-line drug for the treatment of atrial fibrillation complicated with heart failure.
文摘南京电子器件研究所基于芯片微凸点制备工艺和倒装互连工艺,进行了GaAs,GaN等晶圆级异构集成3D芯片互连工艺的研究,实现了芯片与芯片堆叠(Die to die,D2D)到芯片与圆片堆叠(Die to wafer,D2W)的技术性突破。芯粒间采用耐腐蚀、抗氧化、有良好塑性变形的金凸点作为互连材料。
